Combination therapy for high-risk multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new combination of drugs (elotuzumab, isatuximab, bortezomib, lenalidomide, and dexamethasone) for people newly diagnosed with high-risk multiple myeloma. The goal is to see if this combination is safe and effective before and after a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have multiple myeloma that is considered high-risk, which means it may grow or spread more quickly.
- You must be healthy enough to receive high-dose chemotherapy and a stem cell transplant (using your own cells).
- Your disease must be measurable, meaning it can be tracked with blood or urine tests.
- You must have a good performance status (mostly able to take care of yourself, with some restrictions).
- You must not have had any prior treatment for multiple myeloma (except for emergency dexamethasone or one cycle of first-line therapy in some cases).
- You must not have certain other plasma cell disorders or cancer of the plasma cells in your spinal fluid.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of four medicines (isatuximab, bortezomib, lenalidomide, dexamethasone) for people with newly diagnosed high-risk multiple myeloma who are not having a stem cell transplant. The goal is to see if this combination can better control the disease and improve outcomes.
This trial tests a combination of four drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) for people newly diagnosed with multiple myeloma who are either unable or choose not to have a stem cell transplant. The goal is to see if this combination can effectively control the disease.
This trial tests a new combination of drugs (isatuximab, bortezomib, lenalidomide, and dexamethasone) for people who are older or frail and have just been diagnosed with multiple myeloma. It aims to see if this treatment can help control the disease better, especially if certain cancer cells are found in the blood.
This trial tests a combination of study drugs as the first treatment for newly diagnosed multiple myeloma, followed by maintenance based on your risk and response. It aims to improve outcomes while allowing some patients to postpone or avoid a stem cell transplant.
This study tests a new combination of drugs for people newly diagnosed with a high-risk form of multiple myeloma. The goal is to see if this combination is safe and works better than standard treatments.
This trial tests a new combination of two medicines (etentamig and pomalidomide) against standard treatments for people whose multiple myeloma has returned or not responded to therapy. The goal is to see if this combination works better and is safe.
Hear when a new Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.